In keeping, in a multicenter cohort of patients at risk of NASH, it has been reported that homozygosity for the 866A UCP2 variant is associated with protection against liver damage related to NAFLD, especially in patients without T2D [52]. The gene discussed is UCP2; the disease is metabolic dysfunction-associated steatohepatitis.